Article: Genaera Presents EVIZON(TM) Overview and New Trodusquemine Data at Fortis Bank Biotechnology Conference.

PLYMOUTH MEETING, Pa., April 26 /PRNewswire-FirstCall/ -- Genaera Corporation today presented an overview of its development pipeline, including recently announced data on bilateral visual acuity in subjects from Phase II trials of EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD) and promising new pre- clinical data on trodusquemine (MSI-1436), an anti-obesity compound. The data was presented by Genaera's President and Chief Executive Officer, John L. (Jack) Armstrong, Jr. at the 6th Annual Fortis Bank Biotechnology Conference in London, UK.

Mr. Armstrong reviewed previously announced results from Phase II clinical ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!